Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Migraine Articles

A retrospective review of the author's early clinical experience with the CGRP inhibitor erenumab (Aimovig) for the prevention of migraine.
A look at the differences in risk, presentation, and care of migraine between men and women.
Clinicians can help to answer tough questions about homeschooling and school absences when a child is living with a chronic painful condition.
Biohaven has received FDA authorization to dose first subject with BHV-3500, a new third-generation CGRP.
Many biological factors, including sex hormones, have been reported as a major contributor to migraine.
Biohaven, Lilly, and Allergan's new research from the American Headache Society (AHS) meeting.
Headache expert Lawrence Robbins, MD, asks a series of questions clinicians need to address before prescribing the long-awaited CGRP antagonists for migraine prevention.
In this exclusive roundtable, developers recap the data on their CGRP inhibitors, including Aimovig, the first-ever monoclonal antibodies specifically designed to prevent chronic or episodic migraine.
In  this exclusive roundtable, Amgen/Novartis, Allergan, Lilly, and Teva recap the data that is moving their CGRP migraine preventives to the finish line. Introduction to CGRPs by Lawrence Robbins, MD
Men with chronic migraine have been shown to be at a high risk of sleep apnea and other disorders.
Amgen, Novartis, Alder, Allergan, BioHaven, Lilly, and Teva are all anticipating FDA approval of their novel anti-CGRP chronic migraine preventive medications in 2018
CGRP receptor antagonists have been well tolerated in studies.
Findings challenge a 2006 FDA advisory, questioning its validity
Lilly survey results point to need for new headache and migraine treatments as well as patient education.
close X